- Home
- ALXO vs WIMI Comparison
ALXO vs WIMI Comparison
Compare ALXO & WIMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- WIMI
- Stock Information
- Founded
- ALXO 2015
- WIMI 2015
- Country
- ALXO United States
- WIMI China
- Employees
- ALXO N/A
- WIMI 107
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- WIMI Computer Software: Prepackaged Software
- Sector
- ALXO Health Care
- WIMI Technology
- Exchange
- ALXO Nasdaq
- WIMI Nasdaq
- Market Cap
- ALXO 24.0M
- WIMI 23.9M
- IPO Year
- ALXO 2020
- WIMI 2020
- Fundamental
- Price
- ALXO $0.61
- WIMI $3.36
- Analyst Decision
- ALXO Strong Buy
- WIMI
- Analyst Count
- ALXO 6
- WIMI 0
- Target Price
- ALXO $3.30
- WIMI N/A
- AVG Volume (30 Days)
- ALXO 500.5K
- WIMI 7.6M
- Earning Date
- ALXO 08-07-2025
- WIMI 01-01-0001
- Dividend Yield
- ALXO N/A
- WIMI N/A
- EPS Growth
- ALXO N/A
- WIMI N/A
- EPS
- ALXO N/A
- WIMI N/A
- Revenue
- ALXO N/A
- WIMI $84,137,968.00
- Revenue This Year
- ALXO N/A
- WIMI N/A
- Revenue Next Year
- ALXO N/A
- WIMI N/A
- P/E Ratio
- ALXO N/A
- WIMI N/A
- Revenue Growth
- ALXO N/A
- WIMI 19.25
- 52 Week Low
- ALXO $0.40
- WIMI $0.27
- 52 Week High
- ALXO $6.08
- WIMI $2.92
- Technical
- Relative Strength Index (RSI)
- ALXO 61.99
- WIMI 48.98
- Support Level
- ALXO $0.44
- WIMI $3.15
- Resistance Level
- ALXO $0.64
- WIMI $4.48
- Average True Range (ATR)
- ALXO 0.04
- WIMI 0.35
- MACD
- ALXO 0.01
- WIMI -0.01
- Stochastic Oscillator
- ALXO 72.40
- WIMI 22.85
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About WIMI WiMi Hologram Cloud Inc.
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.